Cargando…
Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity
[Image: see text] ATP-binding cassette (ABC)-transporters protect tissues by pumping their substrates out of the cells in many physiological barriers, such as the blood–brain barrier, intestine, liver, and kidney. These substrates include various endogenous metabolites, but, in addition, ABC transpo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497665/ https://www.ncbi.nlm.nih.gov/pubmed/32496785 http://dx.doi.org/10.1021/acs.molpharmaceut.0c00155 |
_version_ | 1783583363450273792 |
---|---|
author | Deng, Feng Ghemtio, Leo Grazhdankin, Evgeni Wipf, Peter Xhaard, Henri Kidron, Heidi |
author_facet | Deng, Feng Ghemtio, Leo Grazhdankin, Evgeni Wipf, Peter Xhaard, Henri Kidron, Heidi |
author_sort | Deng, Feng |
collection | PubMed |
description | [Image: see text] ATP-binding cassette (ABC)-transporters protect tissues by pumping their substrates out of the cells in many physiological barriers, such as the blood–brain barrier, intestine, liver, and kidney. These substrates include various endogenous metabolites, but, in addition, ABC transporters recognize a wide range of compounds, therefore affecting the disposition and elimination of clinically used drugs and their metabolites. Although numerous ABC-transporter inhibitors are known, the underlying mechanism of inhibition is not well characterized. The aim of this study is to deepen our understanding of transporter inhibition by studying the molecular basis of ligand recognition. In the current work, we compared the effect of 44 compounds on the active transport mediated by three ABC transporters: breast cancer resistance protein (BCRP and ABCG2), multidrug-resistance associated protein (MRP2 and ABCC2), and P-glycoprotein (P-gp and ABCB1). Eight compounds were strong inhibitors of all three transporters, while the activity of 36 compounds was transporter-specific. Of the tested compounds, 39, 25, and 11 were considered as strong inhibitors, while 1, 4, and 11 compounds were inactive against BCRP, MRP2, and P-gp, respectively. In addition, six transport-enhancing stimulators were observed for P-gp. In order to understand the observed selectivity, we compared the surface properties of binding cavities in the transporters and performed structure–activity analysis and computational docking of the compounds to known binding sites in the transmembrane domains and nucleotide-binding domains. Based on the results, the studied compounds are more likely to interact with the transmembrane domain than the nucleotide-binding domain. Additionally, the surface properties of the substrate binding site in the transmembrane domains of the three transporters were in line with the observed selectivity. Because of the high activity toward BCRP, we lacked the dynamic range needed to draw conclusions on favorable interactions; however, we identified amino acids in both P-gp and MRP2 that appear to be important for ligand recognition. |
format | Online Article Text |
id | pubmed-7497665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-74976652020-09-18 Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity Deng, Feng Ghemtio, Leo Grazhdankin, Evgeni Wipf, Peter Xhaard, Henri Kidron, Heidi Mol Pharm [Image: see text] ATP-binding cassette (ABC)-transporters protect tissues by pumping their substrates out of the cells in many physiological barriers, such as the blood–brain barrier, intestine, liver, and kidney. These substrates include various endogenous metabolites, but, in addition, ABC transporters recognize a wide range of compounds, therefore affecting the disposition and elimination of clinically used drugs and their metabolites. Although numerous ABC-transporter inhibitors are known, the underlying mechanism of inhibition is not well characterized. The aim of this study is to deepen our understanding of transporter inhibition by studying the molecular basis of ligand recognition. In the current work, we compared the effect of 44 compounds on the active transport mediated by three ABC transporters: breast cancer resistance protein (BCRP and ABCG2), multidrug-resistance associated protein (MRP2 and ABCC2), and P-glycoprotein (P-gp and ABCB1). Eight compounds were strong inhibitors of all three transporters, while the activity of 36 compounds was transporter-specific. Of the tested compounds, 39, 25, and 11 were considered as strong inhibitors, while 1, 4, and 11 compounds were inactive against BCRP, MRP2, and P-gp, respectively. In addition, six transport-enhancing stimulators were observed for P-gp. In order to understand the observed selectivity, we compared the surface properties of binding cavities in the transporters and performed structure–activity analysis and computational docking of the compounds to known binding sites in the transmembrane domains and nucleotide-binding domains. Based on the results, the studied compounds are more likely to interact with the transmembrane domain than the nucleotide-binding domain. Additionally, the surface properties of the substrate binding site in the transmembrane domains of the three transporters were in line with the observed selectivity. Because of the high activity toward BCRP, we lacked the dynamic range needed to draw conclusions on favorable interactions; however, we identified amino acids in both P-gp and MRP2 that appear to be important for ligand recognition. American Chemical Society 2020-06-04 2020-07-06 /pmc/articles/PMC7497665/ /pubmed/32496785 http://dx.doi.org/10.1021/acs.molpharmaceut.0c00155 Text en Copyright © 2020 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. |
spellingShingle | Deng, Feng Ghemtio, Leo Grazhdankin, Evgeni Wipf, Peter Xhaard, Henri Kidron, Heidi Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity |
title | Binding Site Interactions of Modulators of Breast
Cancer Resistance Protein, Multidrug Resistance-Associated Protein
2, and P-Glycoprotein Activity |
title_full | Binding Site Interactions of Modulators of Breast
Cancer Resistance Protein, Multidrug Resistance-Associated Protein
2, and P-Glycoprotein Activity |
title_fullStr | Binding Site Interactions of Modulators of Breast
Cancer Resistance Protein, Multidrug Resistance-Associated Protein
2, and P-Glycoprotein Activity |
title_full_unstemmed | Binding Site Interactions of Modulators of Breast
Cancer Resistance Protein, Multidrug Resistance-Associated Protein
2, and P-Glycoprotein Activity |
title_short | Binding Site Interactions of Modulators of Breast
Cancer Resistance Protein, Multidrug Resistance-Associated Protein
2, and P-Glycoprotein Activity |
title_sort | binding site interactions of modulators of breast
cancer resistance protein, multidrug resistance-associated protein
2, and p-glycoprotein activity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497665/ https://www.ncbi.nlm.nih.gov/pubmed/32496785 http://dx.doi.org/10.1021/acs.molpharmaceut.0c00155 |
work_keys_str_mv | AT dengfeng bindingsiteinteractionsofmodulatorsofbreastcancerresistanceproteinmultidrugresistanceassociatedprotein2andpglycoproteinactivity AT ghemtioleo bindingsiteinteractionsofmodulatorsofbreastcancerresistanceproteinmultidrugresistanceassociatedprotein2andpglycoproteinactivity AT grazhdankinevgeni bindingsiteinteractionsofmodulatorsofbreastcancerresistanceproteinmultidrugresistanceassociatedprotein2andpglycoproteinactivity AT wipfpeter bindingsiteinteractionsofmodulatorsofbreastcancerresistanceproteinmultidrugresistanceassociatedprotein2andpglycoproteinactivity AT xhaardhenri bindingsiteinteractionsofmodulatorsofbreastcancerresistanceproteinmultidrugresistanceassociatedprotein2andpglycoproteinactivity AT kidronheidi bindingsiteinteractionsofmodulatorsofbreastcancerresistanceproteinmultidrugresistanceassociatedprotein2andpglycoproteinactivity |